[1] Siegel, R. L.; Miller, K. D.; Jemal, A. Cancer statistics, 2020. CA-Cancer J. Clin. 2020, 70, 7–30.
[2] Parikh, P. K.; Ghate, M. D. Recent advances in the discovery of small molecule c-Met Kinase inhibitors. Eur. J. Med. Chem. 2018, 143, 1103–1138.
[3] Chen, Y.; Zhang, K.; Li, Y.; Guo, R.; Zhong, G.; He, Q. Oestrogen- related receptor alpha mediates chemotherapy resistance of osteosarcoma cells via regulation of ABCB1. J. Cell. Mol. Med. 2019, 23, 2115–2124.
[4] Maloney, S. M.; Hoover, C. A.; Morejon-Lasso, L. V.; Prosperi, J. R. Mechanisms of Taxane Resistance. Cancers 2020, 12, 3323.
[5] Zou, H.; Li, Y.; Liu, X.; Wu, Z.; Li J.; Ma, Z. Roles of plant-derived bioactive compounds and related microRNAs in cancer therapy. Phytother. Res. 2020, DOI: 10.1002/ptr.6883.
[6] Tej, G.; Nayak, P. K. Mechanistic considerations in chemotherapeutic activity of caffeine. Biomed. Pharmacother. 2018, 105, 312–319.
[7] Mackintosh, C.; Yuan, C.; Ou, F. S.; Zhang, S.; Niedzwiecki, D.; Chang, I. W.; O'Neil, B. H.; Mullen, B. C.; Lenz, H. J.; Blanke, C. D.; Venook, A. P.; Mayer, R. J.; Fuchs, C. S.; Innocenti, F.; Nixon, A. B.; Goldberg, R. M.; O'Reilly, E. M.; Meyerhardt, J. A.; Ng, K. Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. JAMA Oncol. 2020, 6, 1713–1721.
[8] Gapstur, S. M.; Gaudet, M. M.; Wang, Y.; Hodge, R. A.; Um, C. Y.; Hartman, T. J.; McCullough, M. L. Coffee Consumption and Invasive Breast Cancer Incidence among Postmenopausal Women in the Cancer Prevention Study-II Nutrition Cohort. Cancer Epidemiol. Biomarkers Prev. 2020, 29, 2383–2386.
[9] Um, C. Y.; McCullough, M. L.; Guinter, M. A.; Campbell, P. T.; Jacobs, E. J.; Gapstur, S. M. Coffee consumption and risk of colorectal cancer in the Cancer Prevention Study-II Nutrition Cohort. Cancer Epidemiol. 2020, 67, 101730.
[10] Tamura, T.; Wada, K.; Konishi, K.; Goto, Y.; Mizuta, F.; Koda, S.; Hori, A.; Tanabashi, S.; Matsushita, S.; Tokimitsu, N.; Nagata, C. Coffee, Green Tea, and Caffeine Intake and Liver Cancer Risk: A Prospective Cohort Study. Nutr. Cancer. 2018, 70, 1210–1216.
[11] Cui, W. Q.; Wang, S. T.; Pan, D.; Chang, B.; Sang, L. X. Caffeine and its main targets of colorectal cancer. World J. Gastrointest. Oncol. 2020, 12, 149–172.
[12] Edling, C. E.; Selvaggi, F.; Ghonaim, R.; Maffucci, T.; Falasca, M. Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway. Cancer Biol. Ther. 2014, 15, 524–532.
[13] Okano, J.; Nagahara, T.; Matsumoto K.; Murawaki, Y. Caffeine inhibits the proliferation of liver cancer cells and activates the MEK/ERK/EGFR signalling pathway. Basic Clin. Pharmacol. Toxicol. 2008, 102, 543–551.
[14] Cheng, Y. C.; Ding, Y. M.; Hueng, D. Y.; Chen, J. Y.; Chen, Y. Caffeine suppresses the progression of human glioblastoma via cathepsin B and MAPK signaling pathway. J. Nutr. Biochem. 2016, 33, 63–72.
[15] Xu, H.; Hu, L.; Liu, T.; Chen, F.; Li, J.; Xu, J.; Jiang, L.; Xiang, Z.; Wang, X.; Sheng, J. Caffeine Targets G6PDH to Disrupt Redox Homeostasis and Inhibit Renal Cell Carcinoma Proliferation. Front. Cell. Dev. Biol. 2020, 8, 556162.
[16] Huang, Y. W.; Xu, H. H.; Wang, S. M.; Zhao, Y.; Huang, Y. M.; Li, R. B.; Wang, X. J.; Hao, S. M.; Sheng, J. Absorption of caffeine in fermented Pu-er tea is inhibited in mice. Food Funct. 2014, 5, 1520–1528.
[17] Xu, H.; Gan, C.; Gao, Z.; Huang, Y.; Wu, S.; Zhang, D.; Wang, X.; Sheng, J. Caffeine Targets SIRT3 to Enhance SOD2 Activity in Mitochondria. Front. Cell. Dev. Biol. 2020, 8, 822.
[18] Judelson, D. A.; Preston, A. G.; Miller, D. L.; Munoz, C. X.; Kellogg, M. D.; Lieberman, H. R. Effects of theobromine and caffeine on mood and vigilance. J. Clin. Psychopharmacol. 2013, 33, 499–506.
[19] Jacobson, K. A.; Gao, Z. G.; Matricon, P.; Eddy, M. T.; Carlsson, J. Adenosine A2A receptor antagonists: from caffeine to selective non-xanthines. Br. J. Pharmacol. 2020, DOI: 10.1111/bph.15103.
[20] Jacobson, K. A.; Gao, Z. G. Adenosine receptors as therapeutic targets. Nat. Rev. Drug. Discov. 2006, 5, 247–264.
[21] Sek, K.; Molck, C.; Stewart, G. D.; Kats, L.; Darcy, P. K.; Beavis, P. A. Targeting Adenosine Receptor Signaling in Cancer Immunotherapy. Int. J. Mol. Sci. 2018, 19, 3837.
[22] Fredholm, B. B. Astra Award Lecture. Adenosine, adenosine receptors and the actions of caffeine. Pharmacol. Toxicol. 1995, 76, 93–101.
[23] Eini, H.; Frishman, V.; Yulzari, R.; Kachko, L.; Lewis, E. C.; Chaimovitz, C.; Douvdevani, A. Caffeine promotes anti-tumor immune response during tumor initiation: Involvement of the adenosine A2A receptor. Biochem. Pharmacol. 2015, 98, 110–118.
[24] Li, Y. F.; Ouyang, S. H.; Tu, L. F.; Wang, X.; Yuan, W. L.; Wang, G. E.; Wu, Y. P.; Duan, W. J.; Yu, H. M.; Fang, Z. Z.; Kurihara, H.; Zhang, Y.; He, R. R. Caffeine Protects Skin from Oxidative Stress-Induced Senescence through the Activation of Autophagy. Theranostics 2018, 8, 5713–5730.
[25] Spencer, N. Y.; Stanton, R. C. Glucose 6-phosphate dehydrogenase and the kidney. Curr. Opin. Nephrol. Hypertens. 2017, 26, 43–49.
[26] Wang, Y. P.; Zhou, L. S.; Zhao, Y. Z.; Wang, S. W.; Chen, L. L.; Liu, L. X.; Ling, Z. Q.; Hu, F. J.; Sun, Y. P.; Zhang, J. Y.; Yang, C.; Yang, Y.; Xiong, Y.; Guan, K. L.; Ye, D. Regulation of G6PD acetylation by SIRT2 and KAT9 modulates NADPH homeostasis and cell survival during oxidative stress. EMBO J. 2014, 33, 1304–1320.
[27] Zhang, C.; Zhang, Z.; Zhu, Y.; Qin, S. Glucose-6-phosphate dehydrogenase: a biomarker and potential therapeutic target for cancer. Anticancer Agents Med. Chem. 2014, 14, 280–289.
[28] Liberti, M. V.; Dai, Z.; Wardell, S. E.; Baccile, J. A.; Liu, X.; Gao, X.; Baldi, R.; Mehrmohamadi, M.; Johnson, M. O.; Madhukar, N. S.; Shestov, A. A.; Chio, I. I. C.; Elemento, O.; Rathmell, J. C.; Schroeder, F. C.; McDonnell, D. P.; Locasale, J. W. A Predictive Model for Selective Targeting of the Warburg Effect through GAPDH Inhibition with a Natural Product. Cell Metab. 2017, 26, 648–659.
[29] Liou, G. Y.; Storz, P. Reactive oxygen species in cancer. Free Radic. Res. 2010, 44, 479–496.
[30] Waris, G.; Ahsan, H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J. Carcinog. 2006, 5, 14. [31] Sullivan, L. B.; Chandel, N. S. Mitochondrial reactive oxygen species and cancer. Cancer Metab. 2014, 2, 17.
[32] Lu, J.; Zhang, H.; Chen, X.; Zou, Y.; Li, J.; Wang, L.; Wu, M.; Zang, J.; Yu, Y.; Zhuang, W.; Xia, Q.; Wang, J. A small molecule activator of SIRT3 promotes deacetylation and activation of manganese superoxide dismutase. Free Radic. Biol. Med. 2017, 112, 287–297. |